| Literature DB >> 32000703 |
Donghwan Yun1,2, Dong Ki Kim1, Kook-Hwan Oh1, Kwon Wook Joo1, Kyung Chul Moon3, Yon Su Kim1,2, Kyoungbun Lee4, Seung Seok Han5.
Abstract
BACKGROUND: Henoch-Schönlein purpura nephritis (HSPN), a small-vessel vasculitis, shares renal pathological features with immunoglobulin A nephropathy. Oxford classification of immunoglobulin A nephropathy pathology has been updated to the MEST-C score, but its application in HSPN remains unresolved.Entities:
Keywords: End-stage renal disease; Henoch-Schönlein purpura nephritis; MEST-C; Oxford classification
Mesh:
Substances:
Year: 2020 PMID: 32000703 PMCID: PMC6993338 DOI: 10.1186/s12882-020-1691-5
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristics of the study patients
| Child | Adult | |
|---|---|---|
| Age (years) | 9.2 ± 3.6 | 38.6 ± 18.3 |
| Female (%) | 46.0 | 40.0 |
| Body mass index (kg/m2) | 18.6 ± 3.7 | 23.3 ± 3.3 |
| Diabetes mellitus (%) | 0 | 8.1 |
| Hypertension (%) | 2.3 | 8.1 |
| Laboratory findings | ||
| WBC (×103/μL) | 10.2 (7.4–12.7) | 7.5 (5.9–9.7) |
| Hemoglobin (g/dL) | 12.6 (11.3–13.4) | 12.9 (10.7–14.0) |
| BUN (mg/dL) | 12 (10–15) | 14 (11–20) |
| Creatinine (mg/dL) | 0.60 (0.45–0.80) | 1.00 (0.80–1.24) |
| eGFR (mL/min/1.73 m2) | 111.4 (82.4–142.7) | 94.6 (59.5–108.8) |
| Cholesterol (mg/dL) | 219 (182–262) | 177 (150–202) |
| Proteinuria (%) | ||
| – or ± | 16.8 | 17.0 |
| 1+ | 5.3 | 13.0 |
| 2+ | 23.0 | 35.0 |
| ≥ 3+ | 54.9 | 35.0 |
| Hematuria (%) | ||
| – or ± | 8.8 | 11.0 |
| 1+ | 8.0 | 13.0 |
| 2+ | 23.9 | 19.0 |
| ≥ 3+ | 59.3 | 57.0 |
| Treatment (%)a | ||
| ACEi/ARB | 96.5 | 59.7 |
| Steroid | 82.6 | 54.8 |
| Cytotoxic agents | 43.0 | 6.5 |
Data are presented as proportion or mean ± standard deviation or median (interquartile range)
WBC white blood cells, BUN blood urea nitrogen, eGFR estimated glomerular filtration, ACEi angiotensin converting enzyme inhibitor, ARB aldosterone II receptor blocker
aNot available in 27 child and 38 adult patients
Renal pathology findings
| Oxford classification (%) | Child patients | Adult patients | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Non-progression | Progression | Total | Non-progression | Progression | |||
| M1 | 54.9 | 48.9 | 81.0 | 0.008 | 31.0 | 28.6 | 43.8 | 0.249 |
| E1 | 61.9 | 58.7 | 76.2 | 0.136 | 48.0 | 46.4 | 56.3 | 0.471 |
| S1 | 63.7 | 62.0 | 71.4 | 0.415 | 59.0 | 59.5 | 56.3 | 0.807 |
| T1/T2 | 5.3 | 3.3 | 14.3 | 0.042 | 11.0 | 6.0 | 37.5 | 0.002 |
| C1/C2 | 44.2 | 44.6 | 42.9 | 0.887 | 38.0 | 34.5 | 56.3 | 0.101 |
M mesangial hypercellularity, E endocapillary hypercellularity, S segmental glomerulosclerosis, T tubular atrophy and interstitial fibrosis, C cellular or fibrocellular crescents
Fig. 1Renal outcome-free survival curves according to MEST-C scores in child patients. a M0 vs. M1; b E0 vs. E1; c S0 vs. S1; d T0 vs. T1/T2; e C0 vs. C1/C2
Fig. 2Renal outcome-free survival curves according to MEST-C scores in adult patients. a M0 vs. M1; b E0 vs. E1; c S0 vs. S1; d T0 vs. T1/T2; e C0 vs. C1/C2
Prediction of renal outcomes among MEST-C scores
| Parameters | HR (95% CI) from Model 1 | HR (95% CI) from Model 2 | HR (95% CI) from Model 3 | HR (95% CI) from Model 4 | ||||
|---|---|---|---|---|---|---|---|---|
| Child patients | ||||||||
| M1 (vs. M0) | 4.16 (1.394–12.407) | 0.011 | 3.38 (1.101–10.363) | 0.033 | 3.53 (1.118–11.140) | 0.032 | 4.02 (1.217–13.304) | 0.023 |
| E1 (vs. E0) | 2.00 (0.734–5.470) | 0.175 | 2.14 (0.720–6.355) | 0.171 | 1.56 (0.486–5.026) | 0.453 | 1.50 (0.464–4.832) | 0.499 |
| S1 (vs. S0) | 1.43 (0.553–3.675) | 0.463 | 1.44 (0.554–3.762) | 0.452 | 1.36 (0.508–3.642) | 0.540 | 1.35 (0.494–3.672) | 0.560 |
| T1/T2 (vs. T0) | 4.86 (1.406–16.794) | 0.012 | 4.24 (1.124–15.979) | 0.033 | 9.74 (1.920–49.462) | 0.006 | 12.28 (2.728–55.273) | 0.001 |
| C1/C2 (vs. C0) | 0.94 (0.396–2.229) | 0.887 | 0.60 (0.232–1.569) | 0.300 | 0.59 (0.231–1.524) | 0.279 | 0.58 (0.216–1.531) | 0.268 |
| Adult patients | ||||||||
| M1 (vs. M0) | 2.05 (0.756–5.532) | 0.159 | 1.29 (0.420–3.933) | 0.659 | 1.41 (0.411–4.819) | 0.586 | 1.36 (0.410–4.473) | 0.618 |
| E1 (vs. E0) | 1.53 (0.569–4.114) | 0.399 | 0.86 (0.233–3.170) | 0.820 | 0.56 (0.139–2.239) | 0.410 | 0.35 (0.075–1.598) | 0.174 |
| S1 (vs. S0) | 0.80 (0.299–2.159) | 0.664 | 1.01 (0.354–2.907) | 0.979 | 1.15 (0.371–3.547) | 0.812 | 1.02 (0.357–2.898) | 0.974 |
| T1/T2 (vs. T0) | 6.25 (2.265–17.258) | < 0.001 | 5.32 (1.807–15.660) | 0.002 | 4.29 (1.124–16.333) | 0.033 | 4.02 (1.665–9.684) | 0.002 |
| C1/C2 (vs. C0) | 2.43 (0.900–6.553) | 0.080 | 1.95 (0.494–7.717) | 0.340 | 1.57 (0.389–6.334) | 0.526 | 0.85 (0.198–3.639) | 0.825 |
HR Hazard ratio, CI confidence interval
Model 1: Unadjusted
Model 2: Adjusted for other pathological scores
Model 3: Adjusted for model 2 plus age, sex, and estimated glomerular filtration rate
Model 4: Adjusted for model 3 plus proteinuria and hematuria
Summary of studies regarding application of the Oxford classification to patients with Henoch-Schönlein purpura nephritis
| Study | No. of patients | Age | Definition of renal outcome | Significant pathologic parameters | |
|---|---|---|---|---|---|
| Univariate model | Multivariate model | ||||
| Child patients | |||||
| Çakıcı et el. (2019) [ | 75 | < 18 years | < 90 mL/min/1.73 m2 or 50% decrease of eGFR; or persistent PU/HU | S1, T1/T2 | T1/T2b |
| Xu et el. (2018) [ | 104 | < 18 years | < 90 mL/min/1.73 m2 or 50% decrease of eGFR | S1 | Nonec |
| The present study | 113 | < 18 years | ESRD or doubling of sCr | M1, T1/T2 | M1, T1/T2 |
| Adult patients | |||||
| Inagaki et el. (2018) [ | 74 | ≥18 years | ESRD or 30% decrease of eGFR | E1 | E1d |
| Kim et el. (2014)a [ | 61 | ≥16 years | ESRD; or < 60 mL/min/1.73 m2 or ≥ 30% decrease of eGFR | E1, T1/T2, Ca | E1, T1/T2e |
| The present study | 100 | ≥18 years | ESRD or doubling of sCr | T1/T2 | T1/T2 |
ESRD end-stage renal disease, sCr serum creatinine, eGFR estimated glomerular filtration rate, PU proteinuria, HU hematuria
aCrescent formation was defined when crescents were ≥ 50% of the glomeruli, which differs from the updated Oxford classification (C1: 0–25%; C2: ≥25%)
bAdjusted for E, S, T, and estimated glomerular filtration rate
cAdjusted for M, E, S, T, and C
dAdjusted for E, T, C, age, sex, and proteinuria
eAdjusted for E, T, C, hypertension, proteinuria, and estimated glomerular filtration rate
Fig. 3Pooled analysis of renal outcome according to MEST-C scores in children (a) and MEST scores in adults (b)